| Parameters |
Overall |
β-blocker |
RSD |
P-value |
| N |
20 |
10 |
10 |
--- |
| Age (years) |
61 ± 7a |
58 ± 7 |
63 ± 8 |
0.1846 |
| Body mass index, kg/m2 |
27 ± 4a |
26 ± 3 |
28 ± 4 |
0.4695 |
| Male sex (%) |
13 (65%) |
6 (60%) |
7 (70%) |
1 |
| Ethnicity (white) (%) |
13 (65%) |
7 (70%) |
6 (60%) |
1 |
| Hypertension |
20 (100%) |
10 (100%) |
10 (100%) |
1 |
| Type 2 Diabetes Mellitus |
13 (65%) |
6 (60%) |
7 (70%) |
1 |
| Coronary artery disease |
12 (60%) |
6 (60%) |
6 (60%) |
1 |
| Stroke/Transient ischemic attack |
4 (20%) |
2 (20%) |
2 (20%) |
1 |
| Atrial fibrillation duration, months |
47 ± 8a |
46 ± 8 |
48 ± 9 |
0.4908 |
| CHA2DS2-VASc |
3.2 ± 1.3a |
3.0 ± 1.4 |
3.3 ± 1.3 |
0.6319 |
| Antihypertensive |
2.3 ± 0.5a |
2.4 ± 0.5 |
2.2 ± 0.4 |
0.3553 |
| ACE-inhibitors/ARB |
20 (100%) |
10 (100%) |
10 (100%) |
1 |
| Diuretics |
17 (85%) |
9 (90%) |
8 (80%) |
1 |
| DHP calcium channel blockers |
9 (45%) |
5 (50%) |
4 (40%) |
1 |
| 24-hour ABPM, mmHg |
126 ± 6/79 ± 4a |
127 ± 7/79 ± 4 |
125 ± 6/78 ± 3 |
0.6252/0.9151 |
| 24-hour Holter monitoring |
| Heart rate minimum, bpm |
52 ± 7 |
53 ± 8 |
52 ± 7 |
0.7904 |
| Heart rate average, bpm |
110 ± 5 |
109 ± 5 |
111 ± 6 |
0.4895 |
| Heart rate maximum, bpm |
174 ± 11 |
173 ± 10 |
175 ± 12 |
0.7197 |
| aMean ± SD;ABPM, ambulatory blood pressure measurements; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DHP, dihydropyridine; N, number of patients; RSD, renal sympathetic denervation. |
|
